The interaction of glucagon and pentagastrin on the lower oesophageal sphincter in man and dog

H. M. JENNEWIN, F. WALDECK, R. SIEWERT, F. WEISER, AND R. THIMM

From the Department of Pharmacology, C.H. Boehringer Sohn, Ingelheim, and the Surgical Clinic, Göttingen University, West Germany

SUMMARY The effect of glucagon on the pressure inside the lower oesophageal sphincter in conscious human subjects and anaesthetized dogs was investigated using the continuous withdrawal method. Glucagon causes a decrease in sphincteric resting pressure in both man and dog and antagonizes the pentagastrin-induced pressure increase of the lower oesophageal sphincter. In experiments on isolated muscle strips of the lower oesophageal sphincter of dogs glucagon decreases the tension and antagonizes the increase in tension induced by pentagastrin. The elevated pressure in patients suffering from achalasia is significantly reduced by glucagon.

As a result of the investigations of Giles, Mason, Humphries, and Clark (1969), Castell and Harris (1970), and Cohen and Lipshutz (1971) the physiological significance of gastrin in the regulation of lower oesophageal sphincter strength is well documented. Furthermore Cohen and Lipshutz (1971) showed that secretin acts as a gastrin antagonist on the lower oesophageal sphincter. It is known that there is a chemical similarity between secretin and glucagon. Both of these hormones inhibit gastrointestinal motility (Dotevall and Kock, 1963; Hubel, 1972), and in addition, glucagon suppresses gastrin as well as histamine-stimulated gastric acid secretion (Hubel, 1972; Wilson, Ginsberg, Levine, and Washington, 1972). Because of these aspects we have been interested in the action of glucagon and in any possible gastrin antagonism of this hormone on the lower oesophageal sphincter.

Methods

The investigations were performed in 24 conscious human volunteers of both sexes with ages ranging from 20 to 25 years and in four male and six female patients (40 to 65 years of age) suffering from achalasia. In order to measure the maximum pressure inside the lower oesophageal sphincter before and after injection of glucagon the continuous withdrawal method was used (Waldeck, 1972; Waldeck, Jennewein, and Siewert, 1973). In these tests a catheter with four lateral holes, diameter of 4.5 mm, and situated at the same level above its sealed end, was used. After inserting the catheter into the stomach it was withdrawn in the state of expiration at a constant speed (6 mm/sec) from the stomach through the lower oesophageal sphincter into the oesophagus during continuous perfusion (5 ml/min). The pressure changes during withdrawal were continuously recorded on a Helcoscriptor. The pressure profiles obtained reflect the lowest pressure at one of the four holes at any given moment. From these profiles the maximum pressure was taken for further evaluation as this is the most important value in respect of reflux. This maximum pressure is always given in the text. Furthermore the common manometric technique with three perfused open-sided catheters was applied to study patients with achalasia.

In animal experiments beagle and mongrel dogs of both sexes with a body weight of between 10 and 17 kg were used. The animals were lightly anaesthetized with chloralose urethane and then curarized (Gallamine 1 mg/kg). The continuous withdrawal method was used in these experiments in an identical manner as that described above.

In 12 anaesthetized dogs circular muscle strips were dissected from the lower oesophageal sphincter and suspended in an oxygen-bubbled tyrode bath. The tension of the strips was measured by means of an isometric transducer (Grass FT-03e) and was registered on a Grass polygraph. After an equilibration period of 40 min during which the tyrode solution was twice replaced, either pentagastrin (J.C.J. 50, 123) was instilled in such amounts that
the bath concentration was between $10^{-11}$ and $10^{-8}$ g/ml or glucagon was added to achieve a concentration of $10^{-8}$ or $10^{-5}$ g/ml. In further tests the pentagastrin response of muscle strips was tested following the administration of glucagon.

For statistical evaluation of the results the Bartlett test, t test, and Dunnett test (1964) were used.

**Results**

**SINGLE INJECTIONS OF GLUCAGON**

Figure 1 demonstrates that single intravenous injections of glucagon cause a decrease in sphincteric pressure in both man and dog. The doses of 60 µg/kg in man and 100 µg/kg in dogs yield a maximum decrease in sphincteric tone, which is more than 50% in man and nearly 100% in the dog. The effect of single injections of glucagon lasts for about 30 min in both man and dog. As shown by the dose response curve of glucagon in dogs (fig 2) even a dose as low as 1 µg/kg shows a distinct decrease in sphincteric pressure.

**CONTINUOUS INTRAVENOUS INFUSION OF GLUCAGON**

A continuous intravenous infusion of glucagon also causes a reduction in sphincteric tone. As shown in fig 3 a glucagon infusion of 0.5 mg/kg-hr reduces sphincteric pressure in dogs almost completely. Since the blood sugar level increases as a result of this infusion, similar experiments were performed injecting glucose. Neither single injections (1 ml/kg)

nor continuous intravenous infusion (10 ml/kg-hr) of 10% glucose showed any effect on sphincteric pressure in dogs.

**PENTAGASTRIN ANTAGONISM**

In the upper part of fig 4 the typical bell-shaped dose response curve of pentagastrin on the pressure of the lower oesophageal sphincter in dogs is given.

![Graph](https://example.com/graph1.png)

**Fig 1** Effect of single injections of glucagon on the pressure in the lower oesophageal sphincter in man (60 µg/kg intravenously, curve A) and dog (100 µg/kg intravenously, curve B); n = 10, x ± SE.

![Graph](https://example.com/graph2.png)

**Fig 2** Dose response curve of single intravenous injections of glucagon on the pressure in the lower oesophageal sphincter in dogs; n = 10, x ± SE.

![Graph](https://example.com/graph3.png)

**Fig 3** Effects of continuous intravenous infusions of glucagon on the pressure in the lower oesophageal sphincter in dogs; n = 10, x ± SE.

The two lower diagrams in fig 4 demonstrate that there is a flattening in the dose response curve of pentagastrin, which is due to the glucagon infusion. It is to be seen that the degree of flattening depends on the dose of glucagon administered.
In four pilot tests in man a glucagon infusion (750 μg/kg-hr) resulted in a 40% decrease in sphincteric pressure. This low pressure level was not altered by single injections of pentagastrin (0.6 μg/kg). However, it must be mentioned that the administration of pentagastrin during glucagon infusion elicits nausea and vomiting.

EXPERIMENTS ON ISOLATED MUSCLE STRIPS

In 12 experiments on isolated muscle strips from the lower oesophageal sphincter of dogs the tension of the strips was regularly reduced by applying glucagon in the concentrations of 10⁻⁸ and 10⁻⁴ g/ml. The decrease in tone was 18 ± 9% (± SE) after the administration of 10⁻³ g/ml glucagon and 84 ± 23% after 10⁻⁸ g/ml. In fig 5 the white columns reflect a dose-effect curve of pentagastrin on the tension of isolated sphincter strips. They show that a maximum increase in tone is achieved by concentrations of 10⁻⁴ to 10⁻⁸ g/ml. The effect of higher concentrations is considerably smaller.

After establishing a glucagon concentration in the organ bath of 10⁻⁸ g/ml, the consecutive administration of pentagastrin in various doses appears to result in a considerably reduced increase in tone (dashed columns in fig 5). In comparison to the controls, only the difference at 10⁻¹⁰ g/ml pentagastrin is statistically significant (p < 0.05). According to the black columns in fig 5, pretreating the muscle strips with 10⁻⁴ g/ml glucagon significantly inhibits the pentagastrin response (p < 0.001) over the range of 10⁻¹⁰ to 10⁻⁸ g/ml.

GLUCAGON IN ACHALASIA

The effect of glucagon on sphincteric tone was investigated in four male and six female patients, in whom the diagnosis of achalasia was confirmed clinically and cineradiographically. The resting pressure in the lower oesophageal sphincter of these patients was 35 ± 3.9 mm Hg (± SE). This value is significantly (p < 0.01) higher than the resting pressure of 20 healthy subjects, which is 19 ± 2.5 mm Hg (± SE). Intravenous injection of 60 μg/kg glucagon decreases the elevated resting pressure of patients suffering from achalasia significantly (p < 0.002) to a value of 17 ± 2.3 mm Hg (± SE) three minutes after administration. This effect lasts for about 15 minutes.

Discussion

The results demonstrate that glucagon decreases the maximum pressure inside the lower oesophageal sphincter in man and dog, when given as single injections or as continuous infusions. Furthermore, we found that the response of the lower oesophageal
sphincter to pentagastrin is inhibited during infusion of glucagon. Since similar observations were made on isolated muscle strips of the lower oesophageal sphincter in dogs there is good evidence that glucagon is directly affecting it. In addition one has to keep in mind that the effect of glucagon in vivo could also in part be due to the known effect of glucagon suppressing the release of gastrin (Becker, Reeder, Lerman, and Thompson, 1972). It has recently been shown that serum gastrin in normal subjects decreases significantly after rapid intravenous injection of 1 mg of glucagon (Hansky, Soveny, and Korman, 1973). Similar results have been obtained after intravenous infusion of glucagon (30 μg/kg/h) in normal persons, patients with duodenal ulcer, and in dogs before and after a standard meal (Becker, Reeder, and Thompson, 1973). In comparison to secretin, which shifts the dose response curve of gastrin in man (Cohen and Lipshutz, 1971) and of pentagastrin in dogs (Jennewein, Waldeck, and Prahl, 1972) to the right, glucagon causes a flattening of the pentagastrin dose response curve without any lateral shift. In contrast to secretin these results indicate that glucagon might inhibit the pentagastrin response of the lower oesophageal sphincter in a non-competitive way. Therefore, a chemical inhibition of gastrin before reaching the receptor site, as was discussed for secretin (Cohen, and Lipshutz, 1971), seems improbable for glucagon. The finding that glucagon reduces the sensitivity of the lower oesophageal sphincter to pentagastrin could contribute to the glucagon-induced decrease in sphincteric pressure in patients suffering from achalasia, who were shown to be hypersensitive to gastrin (Cohen, Lipshutz, and Hughes, 1971).

Until now it has not been clear whether the effect of glucagon on the lower oesophageal sphincter is a physiological one. The glucagon doses needed to achieve an effect on the lower oesophageal sphincter are relatively high and an effect of endogenously released glucagon on the lower oesophageal sphincter has not yet been demonstrated. It is known, however, that cholecystokinin (CCK) is one of the most potent substances in releasing endogenous glucagon (Unger, Ketterer, Dupré, and Eisentraut, 1967). When CCK is given intravenously in a dose of 3 Ivy U/kg the sphincteric pressure is reduced in man (Giles and Roszkowski, 1972) and dog (Jennewein et al, 1972) although there is no clear dose response curve. The effect of CCK could either be a direct relaxation of the lower oesophageal sphincter or a gastrin antagonistic one, in which glucagon might be involved. Unfortunately the CCK available to us (Karolinska-Institute Sweden) is impure and extensive studies with purer preparations will be necessary to elucidate this aspect further.

Our sincere thanks are due to Mr Kurt Paulus for his valuable technical assistance.

References


The interaction of glucagon and pentagastrin on the lower oesophageal sphincter in man and dog

H. M. Jennewein, F. Waldeck, R. Siewert, F. Weiser and R. Thimm

Gut 1973 14: 861-864
doi: 10.1136/gut.14.11.861

Updated information and services can be found at:
http://gut.bmj.com/content/14/11/861

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/